Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H28INO10.ClH |
| Molecular Weight | 689.877 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(C[C@H](N)[C@H](I)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO
InChI
InChIKey=RIXHOXYAFWQBGU-RUELKSSGSA-N
InChI=1S/C27H28INO10.ClH/c1-10-22(28)13(29)6-17(38-10)39-15-8-27(36,16(31)9-30)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,30,33,35-36H,6-9,29H2,1-2H3;1H/t10-,13-,15-,17-,22+,27-;/m0./s1
Iododoxorubicin is an anthracycline derivative patented by Farmitalia Carlo Erba S.p.A. for cancer treatment. In preclinical studies, Iododoxorubicin has demonstrated significantly reduced levels of cardiotoxicity compared to anthracyclines. Unfortunately, during phase II clinical trials Iododoxorubicin failed to demonstrate efficacy in an advanced breast cancer patient
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
378901
Created by
admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
|
PRIMARY | |||
|
13189887
Created by
admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
|
PRIMARY | |||
|
83943-83-3
Created by
admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
|
PRIMARY | |||
|
DTXSID801004122
Created by
admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
|
PRIMARY | |||
|
31I1O326SE
Created by
admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
